Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare tumor principally due to past exposure to asbestos, a carcinogenic natural mineral fiber that induces genomic and genetic alterations [1]. Lack of curative treatment due to resistance to anti-cancer therapies combined with tumor aggressiveness accounts for the poor prognosis associated to MPM. Despite the significant advances in oncotherapy, MPM is still a challenging cancer to treat [2].

Source: Lung Cancer - October 16, 2018 Category: Cancer & Oncology Authors: Robin Tranchant, Lisa Quetel, Fran çois Montagne, Julien De Wolf, Clement Meiller, Leanne De Koning, Françoise Le Pimpec-Barthes, Jessica Zucman-Rossi, Marie-Claude Jaurand, Didier Jean Source Type: research